Main variables;Main activity, secondary one or a tool necessary for production;Total
Companies that carry out R&D in Biotechnology;Total;1.299
Companies that carry out R&D in Biotechnology;Main;559
Companies that carry out R&D in Biotechnology;Secondary dwellings;230
Companies that carry out R&D in Biotechnology;Tool;510
%Companies according to biotechnology used: Genetic code;Total;30,8
%Companies according to biotechnology used: Genetic code;Main;39,2
%Companies according to biotechnology used: Genetic code;Secondary dwellings;31,4
%Companies according to biotechnology used: Genetic code;Tool;21,3
%Companies according to biotechnology used: Functional units;Total;38,4
%Companies according to biotechnology used: Functional units;Main;45,7
%Companies according to biotechnology used: Functional units;Secondary dwellings;43
%Companies according to biotechnology used: Functional units;Tool;28,3
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Total;21,5
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Main;26,3
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Secondary dwellings;19,8
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;Tool;17,1
%Companies according to biotechnology used: Bioprocesses;Total;50,8
%Companies according to biotechnology used: Bioprocesses;Main;40,7
%Companies according to biotechnology used: Bioprocesses;Secondary dwellings;54,3
%Companies according to biotechnology used: Bioprocesses;Tool;60,2
%Companies according to biotechnology used: Sub-cellular organisms;Total;8,5
%Companies according to biotechnology used: Sub-cellular organisms;Main;12,7
%Companies according to biotechnology used: Sub-cellular organisms;Secondary dwellings;4,6
%Companies according to biotechnology used: Sub-cellular organisms;Tool;5,6
%Companies according to biotechnology used: Bio-computing;Total;24
%Companies according to biotechnology used: Bio-computing;Main;34,7
%Companies according to biotechnology used: Bio-computing;Secondary dwellings;22,1
%Companies according to biotechnology used: Bio-computing;Tool;13,2
%Companies according to biotechnology used: Nanobiotechnology;Total;12,1
%Companies according to biotechnology used: Nanobiotechnology;Main;15,6
%Companies according to biotechnology used: Nanobiotechnology;Secondary dwellings;15,6
%Companies according to biotechnology used: Nanobiotechnology;Tool;6,6
%Companies according to biotechnology used: Other;Total;16,9
%Companies according to biotechnology used: Other;Main;19,2
%Companies according to biotechnology used: Other;Secondary dwellings;20,6
%Companies according to biotechnology used: Other;Tool;12,7
%Company by field(s) of ultimate application of biotechnology use: Human Health;Total;45,5
%Company by field(s) of ultimate application of biotechnology use: Human Health;Main;64,2
%Company by field(s) of ultimate application of biotechnology use: Human Health;Secondary dwellings;36,9
%Company by field(s) of ultimate application of biotechnology use: Human Health;Tool;28,8
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Total;15,5
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Main;17,4
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Secondary dwellings;16
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;Tool;13,1
%Company by field(s) of ultimate application of biotechnology use: Food products;Total;32,3
%Company by field(s) of ultimate application of biotechnology use: Food products;Main;21
%Company by field(s) of ultimate application of biotechnology use: Food products;Secondary dwellings;34,5
%Company by field(s) of ultimate application of biotechnology use: Food products;Tool;43,8
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Total;23,8
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Main;20,7
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Secondary dwellings;30,9
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;Tool;23,9
%Company by field(s) of ultimate application of biotechnology use: Environment;Total;15,6
%Company by field(s) of ultimate application of biotechnology use: Environment;Main;14,1
%Company by field(s) of ultimate application of biotechnology use: Environment;Secondary dwellings;24
%Company by field(s) of ultimate application of biotechnology use: Environment;Tool;13,5
%Company by field(s) of ultimate application of biotechnology use: Industry;Total;13,7
%Company by field(s) of ultimate application of biotechnology use: Industry;Main;14,7
%Company by field(s) of ultimate application of biotechnology use: Industry;Secondary dwellings;18,5
%Company by field(s) of ultimate application of biotechnology use: Industry;Tool;10,6
Personnel in R&D in biotechnology (no. of persons);Total;15.750
Personnel in R&D in biotechnology (no. of persons);Main;6.759
Personnel in R&D in biotechnology (no. of persons);Secondary dwellings;3.644
Personnel in R&D in biotechnology (no. of persons);Tool;5.347
Personnel in R&D in biotechnology (no. of persons): Research personnel;Total;8.379
Personnel in R&D in biotechnology (no. of persons): Research personnel;Main;3.802
Personnel in R&D in biotechnology (no. of persons): Research personnel;Secondary dwellings;2.145
Personnel in R&D in biotechnology (no. of persons): Research personnel;Tool;2.433
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Total;7.371
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Main;2.957
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Secondary dwellings;1.500
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;Tool;2.914
Personnel in R&D in biotechnology (no. of persons). Women;Total;8.711
Personnel in R&D in biotechnology (no. of persons). Women;Main;3.890
Personnel in R&D in biotechnology (no. of persons). Women;Secondary dwellings;2.040
Personnel in R&D in biotechnology (no. of persons). Women;Tool;2.782
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Total;4.510
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Main;2.078
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Secondary dwellings;1.196
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel;Tool;1.236
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Total;4.200
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Main;1.811
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Secondary dwellings;843
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel;Tool;1.546
Personnel in R&D in biotechnology (FTE);Total;11.528,6
Personnel in R&D in biotechnology (FTE);Main;5.389
Personnel in R&D in biotechnology (FTE);Secondary dwellings;2.417,3
Personnel in R&D in biotechnology (FTE);Tool;3.722,4
Personnel in R&D in biotechnology (FTE): Research personnel;Total;6.342,7
Personnel in R&D in biotechnology (FTE): Research personnel;Main;3.157
Personnel in R&D in biotechnology (FTE): Research personnel;Secondary dwellings;1.493,6
Personnel in R&D in biotechnology (FTE): Research personnel;Tool;1.692,1
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Total;5.185,9
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Main;2.232
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Secondary dwellings;923,7
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;Tool;2.030,3
Personnel in R&D in biotechnology (FTE). Women;Total;6.539,7
Personnel in R&D in biotechnology (FTE). Women;Main;3.168,1
Personnel in R&D in biotechnology (FTE). Women;Secondary dwellings;1.378,1
Personnel in R&D in biotechnology (FTE). Women;Tool;1.993,6
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Total;3.455,7
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Main;1.734,1
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Secondary dwellings;839,4
Personnel in R&D in biotechnology (FTE). Women: Research personnel;Tool;882,2
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Total;3.084
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Main;1.434
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Secondary dwellings;538,7
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;Tool;1.111,4
Internal expenditure on R&D (thousands of euros);Total;1.038.582
Internal expenditure on R&D (thousands of euros);Main;519.104
Internal expenditure on R&D (thousands of euros);Secondary dwellings;204.849
Internal expenditure on R&D (thousands of euros);Tool;314.630
1) By nature of the expense: Current expenses;Total;940.091
1) By nature of the expense: Current expenses;Main;466.051
1) By nature of the expense: Current expenses;Secondary dwellings;179.259
1) By nature of the expense: Current expenses;Tool;294.780
1.1) Remuneration to research personnel;Total;321.570
1.1) Remuneration to research personnel;Main;164.629
1.1) Remuneration to research personnel;Secondary dwellings;73.301
1.1) Remuneration to research personnel;Tool;83.640
1.2) Remuneration to technicians and auxiliary personnel;Total;194.836
1.2) Remuneration to technicians and auxiliary personnel;Main;85.747
1.2) Remuneration to technicians and auxiliary personnel;Secondary dwellings;33.173
1.2) Remuneration to technicians and auxiliary personnel;Tool;75.916
1.3) Other current expenses;Total;423.685
1.3) Other current expenses;Main;215.675
1.3) Other current expenses;Secondary dwellings;72.786
1.3) Other current expenses;Tool;135.225
2) By nature of the expense: Capital expenses;Total;98.492
2) By nature of the expense: Capital expenses;Main;53.052
2) By nature of the expense: Capital expenses;Secondary dwellings;25.589
2) By nature of the expense: Capital expenses;Tool;19.850
2.1) Land and buildings;Total;10.199
2.1) Land and buildings;Main;5.434
2.1) Land and buildings;Secondary dwellings;2.616
2.1) Land and buildings;Tool;2.149
2.2) Equipment and instruments;Total;72.584
2.2) Equipment and instruments;Main;36.725
2.2) Equipment and instruments;Secondary dwellings;20.086
2.2) Equipment and instruments;Tool;15.773
2.3) Acquisition of specific R+D software;Total;5.721
2.3) Acquisition of specific R+D software;Main;2.513
2.3) Acquisition of specific R+D software;Secondary dwellings;2.103
2.3) Acquisition of specific R+D software;Tool;1.104
2.4) Otros productos de propiedad intelectual específicos para I+D;Total;9.987
2.4) Otros productos de propiedad intelectual específicos para I+D;Main;8.379
2.4) Otros productos de propiedad intelectual específicos para I+D;Secondary dwellings;784
2.4) Otros productos de propiedad intelectual específicos para I+D;Tool;823
1.1) By origin of the funds: Own funds;Total;711.488
1.1) By origin of the funds: Own funds;Main;314.308
1.1) By origin of the funds: Own funds;Secondary dwellings;155.688
1.1) By origin of the funds: Own funds;Tool;241.492
1.2) By origin of the funds: From companies;Total;121.738
1.2) By origin of the funds: From companies;Main;80.154
1.2) By origin of the funds: From companies;Secondary dwellings;10.983
1.2) By origin of the funds: From companies;Tool;30.601
1.3) By origin of the funds: Public Administration funds;Total;107.477
1.3) By origin of the funds: Public Administration funds;Main;61.083
1.3) By origin of the funds: Public Administration funds;Secondary dwellings;16.108
1.3) By origin of the funds: Public Administration funds;Tool;30.285
1.4) By origin of the funds: From Universities;Total;192
1.4) By origin of the funds: From Universities;Main;68
1.4) By origin of the funds: From Universities;Secondary dwellings;14
1.4) By origin of the funds: From Universities;Tool;111
1.5) By origin of the funds: From non profit private institutions;Total;10.756
1.5) By origin of the funds: From non profit private institutions;Main;9.444
1.5) By origin of the funds: From non profit private institutions;Secondary dwellings;0
1.5) By origin of the funds: From non profit private institutions;Tool;1.312
1.6) By origin of the funds: Foreign funds;Total;86.931
1.6) By origin of the funds: Foreign funds;Main;54.046
1.6) By origin of the funds: Foreign funds;Secondary dwellings;22.055
1.6) By origin of the funds: Foreign funds;Tool;10.829
Purchase of R&D services in biotechnology (thousands of euros);Total;145.557
Purchase of R&D services in biotechnology (thousands of euros);Main;105.405
Purchase of R&D services in biotechnology (thousands of euros);Secondary dwellings;16.127
Purchase of R&D services in biotechnology (thousands of euros);Tool;24.025
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Total;95.915
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Main;74.486
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Secondary dwellings;14.004
Purchase of R&D services in biotechnology (thousands of euros): In Spain;Tool;7.425
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Total;49.642
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Main;30.919
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Secondary dwellings;2.123
Purchase of R&D services in biotechnology (thousands of euros): Abroad;Tool;16.600
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Total;40,2
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Main;49,4
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Secondary dwellings;39,8
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;Tool;30,4
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Total;13,2
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Main;12,5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Secondary dwellings;15,9
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;Tool;12,7
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Total;19
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Main;21,5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Secondary dwellings;20
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;Tool;15,7
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Total;11,5
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Main;10,4
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Secondary dwellings;15,1
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;Tool;11,1
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Total;15,9
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Main;16,1
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Secondary dwellings;23,5
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;Tool;12,1
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Total;17
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Main;20,6
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Secondary dwellings;19,3
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;Tool;11,9
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Total;16,4
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Main;16,3
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Secondary dwellings;23,1
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;Tool;13,6
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Total;40,5
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Main;46,9
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Secondary dwellings;44,1
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;Tool;31,9
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Total;55
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Main;65,2
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Secondary dwellings;55,1
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;Tool;43,8
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Total;21,9
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Main;24,5
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Secondary dwellings;25
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;Tool;17,6
% Companies with income of an international origin related to biotechnological activities;Total;23,5
% Companies with income of an international origin related to biotechnological activities;Main;33,3
% Companies with income of an international origin related to biotechnological activities;Secondary dwellings;19,8
% Companies with income of an international origin related to biotechnological activities;Tool;14,4
% Turnover representing income of an international origin related to biotechnological activities;Total;1,9
% Turnover representing income of an international origin related to biotechnological activities;Main;12,1
% Turnover representing income of an international origin related to biotechnological activities;Secondary dwellings;1,2
% Turnover representing income of an international origin related to biotechnological activities;Tool;1,3
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Total;61,6
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Main;44
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Secondary dwellings;79,9
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;Tool;60,4
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Total;38,4
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Main;56
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Secondary dwellings;20,1
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;Tool;39,6
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Total;87,6
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Main;97
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Secondary dwellings;73,4
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;Tool;96,5
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;10,9
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Main;1,5
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Secondary dwellings;25,9
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Tool;0,9
% Income of an international origin related with activities according to the classification: Operating source abroad;Total;1,1
% Income of an international origin related with activities according to the classification: Operating source abroad;Main;1,3
% Income of an international origin related with activities according to the classification: Operating source abroad;Secondary dwellings;0,7
% Income of an international origin related with activities according to the classification: Operating source abroad;Tool;1,3
% Income of an international origin related with activities according to the classification: Other;Total;0,4
% Income of an international origin related with activities according to the classification: Other;Main;0,2
% Income of an international origin related with activities according to the classification: Other;Secondary dwellings;0
% Income of an international origin related with activities according to the classification: Other;Tool;1,3